Kathryn A Ellis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1963299/publications.pdf

Version: 2024-02-01

21540 31976 114 14,096 142 53 citations h-index g-index papers 181 181 181 14555 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 844-852.	0.8	1,863
2	Amyloid \hat{l}^2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurology, The, 2013, 12, 357-367.	10.2	1,738
3	Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiology of Aging, 2010, 31, 1275-1283.	3.1	885
4	Longitudinal assessment of ${\rm A\hat{l}^2}$ and cognition in aging and Alzheimer disease. Annals of Neurology, 2011, 69, 181-192.	5.3	730
5	The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. International Psychogeriatrics, 2009, 21, 672-687.	1.0	661
6	Implementation of subjective cognitive decline criteria in research studies. Alzheimer's and Dementia, 2017, 13, 296-311.	0.8	375
7	Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease. Archives of Neurology, 2012, 69, 1318.	4.5	348
8	Relationship between atrophy and βâ€amyloid deposition in Alzheimer disease. Annals of Neurology, 2010, 67, 317-324.	5.3	322
9	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. Journal of Alzheimer's Disease, 2015, 48, S63-S86.	2.6	317
10	Increased Risk of Cognitive Impairment in Patients With Diabetes Is Associated With Metformin. Diabetes Care, 2013, 36, 2981-2987.	8.6	308
11	Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB–PET longitudinal study. Brain, 2012, 135, 2126-2139.	7.6	222
12	Predicting Alzheimer disease with βâ€amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing. Annals of Neurology, 2013, 74, 905-913.	5.3	194
13	Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain, 2014, 137, 221-231.	7.6	182
14	Cerebral Microbleeds: A Review of Clinical, Genetic, and Neuroimaging Associations. Frontiers in Neurology, 2014, 4, 205.	2.4	176
15	Cross-sectional and Longitudinal Analysis of the Relationship Between AÎ ² Deposition, Cortical Thickness, and Memory in Cognitively Unimpaired Individuals and in Alzheimer Disease. JAMA Neurology, 2013, 70, 903.	9.0	170
16	Amyloid-β, Anxiety, and Cognitive Decline in Preclinical Alzheimer Disease. JAMA Psychiatry, 2015, 72, 284.	11.0	160
17	Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer's disease. BMC Psychology, 2013, 1, 30.	2.1	15 3
18	Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study. Neuropsychologia, 2011, 49, 2384-2390.	1.6	139

#	Article	IF	CITATIONS
19	Combined physical and cognitive training for older adults with and without cognitive impairment: A systematic review and network meta-analysis of randomized controlled trials. Ageing Research Reviews, 2021, 66, 101232.	10.9	136
20	Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 796-804.	0.8	135
21	Independent contribution of temporal β-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. Brain, 2011, 134, 798-807.	7.6	132
22	Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain, 2010, 133, 3349-3358.	7.6	130
23	Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans. International Journal of Neuropsychopharmacology, 2006, 9, 175.	2.1	126
24	Incidence of cerebral microbleeds in preclinical Alzheimer disease. Neurology, 2014, 82, 1266-1273.	1.1	125
25	Plasma Amyloid- \hat{l}^2 as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging. Journal of Alzheimer's Disease, 2010, 20, 1233-1242.	2.6	122
26	Effects of Anticholinergic Drugs on Cognitive Function in Older Australians: Results from the AIBL Study. Dementia and Geriatric Cognitive Disorders, 2011, 31, 173-178.	1.5	115
27	Acute effects of breaking up prolonged sitting on fatigue and cognition: a pilot study. BMJ Open, 2016, 6, e009630.	1.9	115
28	Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 53-61.	0.8	114
29	Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. Journal of Clinical and Experimental Neuropsychology, 2012, 34, 345-358.	1.3	111
30	Sedentary behavior as a risk factor for cognitive decline? A focus on the influence of glycemic control in brain health. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 291-300.	3.7	111
31	BDNF Val 66 Met, A \hat{l}^2 amyloid, and cognitive decline in preclinical Alzheimer's disease. Neurobiology of Aging, 2013, 34, 2457-2464.	3.1	109
32	Muscarinic and nicotinic receptor modulation of object and spatial -back working memory in humans. Pharmacology Biochemistry and Behavior, 2005, 81, 575-584.	2.9	108
33	Stronger effect of amyloid load than <i>APOE</i> genotype on cognitive decline in healthy older adults. Neurology, 2012, 79, 1645-1652.	1.1	96
34	Comparison of MR-less PiB SUVR quantification methods. Neurobiology of Aging, 2015, 36, S159-S166.	3.1	96
35	Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies—Gains from AIBL and DIAN Cohort Studies. Journal of Alzheimer's Disease, 2018, 62, 965-992.	2.6	96
36	Three-Month Stability of the CogState Brief Battery in Healthy Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease: Results from the Australian Imaging, Biomarkers, and Lifestyle-Rate of Change Substudy (AIBL-ROCS). Archives of Clinical Neuropsychology, 2013, 28, 320-330.	0.5	90

3

#	Article	IF	CITATIONS
37	An increased neutrophil–lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation. Journal of Neuroimmunology, 2014, 273, 65-71.	2.3	87
38	Homocysteine, Vitamin B12, and Folic Acid Levels in Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Elderly: Baseline Characteristics in Subjects of the Australian Imaging Biomarker Lifestyle Study. Journal of Alzheimer's Disease, 2011, 27, 909-922.	2.6	83
39	The pharmacology of human working memory. International Journal of Neuropsychopharmacology, 2001, 4, 299-313.	2.1	81
40	Appearance modeling of 11C PiB PET images: Characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. NeuroImage, 2008, 43, 430-439.	4.2	81
41	Among Vitamin B12 Deficient Older People, High Folate Levels are Associated with Worse Cognitive Function: Combined Data from Three Cohorts. Journal of Alzheimer's Disease, 2014, 39, 661-668.	2.6	76
42	Effect of BDNF Val66Met on Memory Decline and Hippocampal Atrophy in Prodromal Alzheimer's Disease: A Preliminary Study. PLoS ONE, 2014, 9, e86498.	2.5	75
43	APOE Îμ4 moderates amyloid-related memory decline in preclinical Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1239-1244.	3.1	75
44	Assessment of the DTIâ€ALPS Parameter Along the Perivascular Space in Older Adults at Risk of Dementia. Journal of Neuroimaging, 2021, 31, 569-578.	2.0	68
45	Genetic algorithm with logistic regression for prediction of progression to Alzheimer's disease. BMC Bioinformatics, 2014, 15, S11.	2.6	67
46	${\sf A}{\sf \hat{I}}^2$ and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 743.	0.8	66
47	Amyloid-Î ² Related Memory Decline is not Associated with Subjective or Informant Rated Cognitive Impairment in Healthy Adults. Journal of Alzheimer's Disease, 2014, 43, 677-686.	2.6	63
48	Rapid Decline in Episodic Memory in Healthy Older Adults with High Amyloid-β. Journal of Alzheimer's Disease, 2013, 33, 675-679.	2.6	62
49	Influence of population versus convenience sampling on sample characteristics in studies of cognitive aging. Annals of Epidemiology, 2014, 24, 63-71.	1.9	61
50	Distinct effects of acute exercise and breaks in sitting on working memory and executive function in older adults: a three-arm, randomised cross-over trial to evaluate the effects of exercise with and without breaks in sitting on cognition. British Journal of Sports Medicine, 2020, 54, 776-781.	6.7	60
51	Memory improvements in elderly women following 16Âweeks treatment with a combined multivitamin, mineral and herbal supplement. Psychopharmacology, 2012, 220, 351-365.	3.1	59
52	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. Science Advances, 2019, 5, eaau7220.	10.3	59
53	Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease. Journal of Alzheimer's Disease Reports, 2021, 5, 443-468.	2.2	59
54	Influence of <i>BDNF</i> Val66Met on the relationship between physical activity and brain volume. Neurology, 2014, 83, 1345-1352.	1.1	58

#	Article	IF	CITATIONS
55	Addressing population aging and Alzheimer's disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2010, 6, 291-296.	0.8	53
56	Exploring the temporal dynamics of the spatial working memory n-back task using steady state visual evoked potentials (SSVEP). NeuroImage, 2006, 31, 1741-1751.	4.2	51
57	$\hat{A^2}$ amyloid, cognition, and <i>APOE</i> genotype in healthy older adults. Alzheimer's and Dementia, 2013, 9, 538-545.	0.8	51
58	Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated inÂPET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers andÂLifestyle (AIBL) study. Journal of Alzheimer's Disease, 2015, 48, 175-187.	2.6	47
59	Longitudinal Analysis of Serum Copper and Ceruloplasmin in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 34, 171-182.	2.6	46
60	Subjective Memory Complaints in APOE É 4 Carriers are Associated with High Amyloid-Î ² Burden. Journal of Alzheimer's Disease, 2016, 49, 1115-1122.	2.6	45
61	Physical activity program preferences and perspectives of older adults with and without cognitive impairment. Asia-Pacific Psychiatry, 2014, 6, 179-190.	2.2	44
62	Physical activity for cognitive health: what advice can we give to older adults with subjective cognitive decline and mild cognitive impairment?. Dialogues in Clinical Neuroscience, 2019, 21, 61-68.	3.7	44
63	Relationship between Memory Performance and β-Amyloid Deposition at Different Stages of Alzheimer's Disease. Neurodegenerative Diseases, 2012, 10, 141-144.	1.4	43
64	MR-Less Surface-Based Amyloid Assessment Based on 11C PiB PET. PLoS ONE, 2014, 9, e84777.	2.5	43
65	Phenomenological characterization of memory complaints in preclinical and prodromal Alzheimer's disease Neuropsychology, 2015, 29, 571-581.	1.3	43
66	Decline in Cognitive Function over 18 Months in Healthy Older Adults with High Amyloid- \hat{l}^2 . Journal of Alzheimer's Disease, 2013, 34, 861-871.	2.6	42
67	Plasma Amyloid- \hat{l}^2 Levels are Significantly Associated with a Transition Toward Alzheimer's Disease as Measured by Cognitive Decline and Change in Neocortical Amyloid Burden. Journal of Alzheimer's Disease, 2014, 40, 95-104.	2.6	41
68	Protocol for a randomized controlled trial evaluating the effect of physical activity on delaying the progression of white matter changes on MRI in older adults with memory complaints and mild cognitive impairment: The AIBL Active trial. BMC Psychiatry, 2012, 12, 167.	2.6	40
69	Relationships Between Performance on the Cogstate Brief Battery, Neurodegeneration, and AÂ Accumulation in Cognitively Normal Older Adults and Adults with MCI. Archives of Clinical Neuropsychology, 2015, 30, 49-58.	0.5	40
70	Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing. International Psychogeriatrics, 2012, 24, 197-204.	1.0	39
71	Morning exercise mitigates the impact of prolonged sitting on cerebral blood flow in older adults. Journal of Applied Physiology, 2019, 126, 1049-1055.	2.5	39
72	Rapid cognitive decline in Alzheimer's disease: a literature review. International Review of Psychiatry, 2013, 25, 650-658.	2.8	38

#	Article	IF	Citations
73	Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). International Psychogeriatrics, 2014, 26, 543-554.	1.0	37
74	A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease. Journal of Molecular Neuroscience, 2016, 60, 354-361.	2.3	37
75	Cognitive Decline in Adults with Amnestic Mild Cognitive Impairment and High Amyloid-Î ² : Prodromal Alzheimer's Disease, 2013, 33, 1167-1176.	2.6	34
76	The effects of a protein enriched diet with lean red meat combined with a multi-modal exercise program on muscle and cognitive health and function in older adults: study protocol for a randomised controlled trial. Trials, 2015, 16, 339.	1.6	34
77	Cognitive consequences of high $A\hat{l}^2$ amyloid in mild cognitive impairment and healthy older adults: Implications for early detection of Alzheimerâ \in [™] s disease Neuropsychology, 2013, 27, 322-332.	1.3	33
78	Effect of Morning Exercise With or Without Breaks in Prolonged Sitting on Blood Pressure in Older Overweight/Obese Adults. Hypertension, 2019, 73, 859-867.	2.7	33
79	Impact of APOE-ε4 carriage on the onset and rates of neocortical Aβ-amyloid deposition. Neurobiology of Aging, 2020, 95, 46-55.	3.1	32
80	Self and informant memory concerns align in healthy memory complainers and in early stages of mild cognitive impairment but separate with increasing cognitive impairment. Age and Ageing, 2015, 44, 1012-1019.	1.6	31
81	Anxiety symptoms, cerebral amyloid burden and memory decline in healthy older adults without dementia: 3-year prospective cohort study. British Journal of Psychiatry, 2014, 204, 400-401.	2.8	29
82	Lack of reliable evidence for a distinctive $\hat{l}\mu4\hat{a}$ related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study. Brain, 2013, 136, 2201-2216.	7.6	28
83	Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study. Journal of Alzheimer's Disease, 2015, 46, 1079-1089.	2.6	28
84	Effect of a 24-month physical activity program on brain changes in older adults at risk of Alzheimer's disease: the AIBL active trial. Neurobiology of Aging, 2020, 89, 132-141.	3.1	28
85	Longitudinal cognitive decline in the AIBL cohort: The role of APOE $\hat{l}\mu 4$ status. Neuropsychologia, 2015, 75, 411-419.	1.6	27
86	Amyloid burden and incident depressive symptoms in preclinical Alzheimer's disease. Journal of Affective Disorders, 2018, 229, 269-274.	4.1	27
87	Examining the nature of impairment in visual paired associate learning in amnestic mild cognitive impairment Neuropsychology, 2011, 25, 752-762.	1.3	25
88	The association of $\hat{Al^2}$ amyloid and composite cognitive measures in healthy older adults and MCI. International Psychogeriatrics, 2013, 25, 1667-1677.	1.0	24
89	A â€^Disease Severity Index' to identify individuals with Subjective Memory Decline who will progress to mild cognitive impairment or dementia. Scientific Reports, 2017, 7, 44368.	3.3	23
90	Associations of neighborhood environment with brain imaging outcomes in the Australian Imaging, Biomarkers and Lifestyle cohort. Alzheimer's and Dementia, 2017, 13, 388-398.	0.8	23

#	Article	IF	CITATIONS
91	Amyloid-Related Memory Decline in Preclinical Alzheimer's Disease Is Dependent on APOE Îμ4 and Is Detectable over 18-Months. PLoS ONE, 2015, 10, e0139082.	2.5	22
92	Disclosing a dementia diagnosis: what do patients and family consider important?. International Psychogeriatrics, 2014, 26, 1263-1272.	1.0	21
93	Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms. Journal of Alzheimer's Disease, 2017, 61, 169-183.	2.6	21
94	Effect of lean red meat combined with a multicomponent exercise program on muscle and cognitive function in older adults: a 6-month randomized controlled trial. American Journal of Clinical Nutrition, 2020, 112, 113-128.	4.7	21
95	Research and standardization in Alzheimer's trials: Reaching international consensus. , 2013, 9, 160-168.		20
96	Trajectories of depressive and anxiety symptoms in older adults: a 6â€year prospective cohort study. International Journal of Geriatric Psychiatry, 2018, 33, 405-413.	2.7	20
97	Physical activity for older Australians with mild cognitive impairment or subjective cognitive decline – A narrative review to support guideline development. Journal of Science and Medicine in Sport, 2020, 23, 913-920.	1.3	20
98	Baseline Amnestic Severity Predicts Progression From Amnestic Mild Cognitive Impairment to Alzheimer Disease Dementia at 3 Years. Alzheimer Disease and Associated Disorders, 2018, 32, 190-196.	1.3	19
99	Association of Plasma Aß Peptides with Blood Pressure in the Elderly. PLoS ONE, 2011, 6, e18536.	2.5	19
100	What is frontotemporal dementia?. Maturitas, 2014, 79, 216-219.	2.4	18
101	A Randomized Controlled Trial of Adherence to a 24-Month Home-Based Physical Activity Program and the Health Benefits for Older Adults at Risk of Alzheimer's Disease: The AIBL Active-Study. Journal of Alzheimer's Disease, 2019, 70, S187-S205.	2.6	18
102	Cortical surface mapping using topology correction, partial flattening and 3D shape context-based non-rigid registration for use in quantifying atrophy in Alzheimer's disease. Journal of Neuroscience Methods, 2012, 205, 96-109.	2.5	17
103	Combined effects of continuous exercise and intermittent active interruptions to prolonged sitting on postprandial glucose, insulin, and triglycerides in adults with obesity: a randomized crossover trial. International Journal of Behavioral Nutrition and Physical Activity, 2020, 17, 152.	4.6	16
104	Combined D1/D2 receptor stimulation under conditions of dopamine depletion impairs spatial working memory performance in humans. Psychopharmacology, 2005, 181, 771-780.	3.1	15
105	The cognitive effects of modulating the glycine site of the NMDA receptor with highâ€dose glycine in healthy controls. Human Psychopharmacology, 2008, 23, 151-159.	1.5	15
106	Enabling a multidisciplinary approach to the study of ageing and Alzheimer's disease: An update from the Australian Imaging Biomarkers and Lifestyle (AIBL) study. International Review of Psychiatry, 2013, 25, 699-710.	2.8	15
107	Age-related changes to the neural correlates of working memory which emerge after midlife. Frontiers in Aging Neuroscience, 2014, 6, 70.	3.4	15
108	Short term stability of verbal memory impairment in mild cognitive impairment and Alzheimer's disease measured using the International Shopping List Test. Journal of Clinical and Experimental Neuropsychology, 2012, 34, 853-863.	1.3	13

#	Article	IF	Citations
109	Relationship of Established Cardiovascular Risk Factors and Peripheral Biomarkers on Cognitive Function in Adults at Risk of Cognitive Deterioration. Journal of Alzheimer's Disease, 2020, 74, 163-171.	2.6	13
110	Tyrosine depletion alters cortical and limbic blood flow but does not modulate spatial working memory performance or task-related blood flow in humans. Human Brain Mapping, 2007, 28, 1136-1149.	3.6	12
111	Health professionals' and students' perceptions of elder abuse. Australasian Journal on Ageing, 2013, 32, 48-51.	0.9	10
112	Personal Memory Function in Mild Cognitive Impairment and Subjective Memory Complaints: Results from the Australian Imaging, Biomarkers, and Lifestyle (AIBL) Study of Ageing. Journal of Alzheimer's Disease, 2014, 40, 551-561.	2.6	10
113	A randomized controlled trial of physical activity with individual goal-setting and volunteer mentors to overcome sedentary lifestyle in older adults at risk of cognitive decline: the INDIGO trial protocol. BMC Geriatrics, 2017, 17, 215.	2.7	10
114	Interacting effects of exercise with breaks in sitting time on cognitive and metabolic function in older adults: Rationale and design of a randomised crossover trial. Mental Health and Physical Activity, $2018, 15, 11-16$.	1.8	10
115	Autobiographical narratives relate to Alzheimer's disease biomarkers in older adults. International Psychogeriatrics, 2014, 26, 1737-1746.	1.0	9
116	Semiâ€automated hippocampal segmentation in people with cognitive impairment using an age appropriate template for registration. Journal of Magnetic Resonance Imaging, 2015, 42, 1631-1638.	3.4	9
117	Why attend a memory clinic? What do patients and their families want and/or expect?. Australasian Journal on Ageing, 2016, 35, 220-224.	0.9	9
118	Predictors of Workplace Disability in a Premanifest Huntington's Disease Cohort. Journal of Neuropsychiatry and Clinical Neurosciences, 2018, 30, 115-121.	1.8	9
119	Ethnic Differences in Barriers and Enablers to Physical Activity Among Older Adults. Frontiers in Public Health, 2021, 9, 691851.	2.7	9
120	Baseline White Matter Is Associated With Physical Fitness Change in Preclinical Alzheimer's Disease. Frontiers in Aging Neuroscience, 2020, 12, 115.	3.4	7
121	Dementia knowledge and associated factors among older Chinese adults: a cross-national comparison between Melbourne and Beijing. International Psychogeriatrics, 2021, 33, 1057-1067.	1.0	7
122	Targeted physical activity for older adults with mild cognitive impairment and subjective cognitive decline. Medical Journal of Australia, 2019, 210, 394.	1.7	6
123	Advances in structural and molecular neuroimaging in Alzheimer's disease. Medical Journal of Australia, 2011, 194, S20-3.	1.7	5
124	Comparative analysis of the Cancer Council of Victoria and the online Commonwealth Scientific and Industrial Research Organisation FFQ. British Journal of Nutrition, 2015, 114, 1683-1693.	2.3	5
125	Alterations in dorsal and ventral posterior cingulate connectivity in APOE <i>$\hat{l}\mu$</i> 4 carriers at risk of Alzheimer's disease. BJPsych Open, 2015, 1, 139-148.	0.7	5
126	Trajectories of irregular word reading ability as a proxy for premorbid intelligence in Alzheimer's disease, mild cognitive impairment, and healthy aging: A longitudinal study Psychological Assessment, 2018, 30, 1308-1316.	1.5	5

#	Article	IF	CITATIONS
127	Response to Comment on Moore et al. Increased Risk of Cognitive Impairment in Patients With Diabetes Is Associated With Metformin. Diabetes Care 2013;36:2981–2987. Diabetes Care, 2014, 37, e151-e151.	8.6	4
128	A Randomized Controlled Trial on the Effects of a 6-Month Home-Based Physical Activity Program with Individual Goal-Setting and Volunteer Mentors on Physical Activity, Adherence, and Physical Fitness in Inactive Older Adults at Risk of Cognitive Decline: The INDIGO Study. Journal of Alzheimer's Disease, 2021, 84, 207-226.	2.6	4
129	Balance on the Brain: a randomised controlled trial evaluating the effect of a multimodal exercise programme on physical performance, falls, quality of life and cognition for people with mild cognitive impairment—study protocol. BMJ Open, 2022, 12, e054725.	1.9	4
130	A webâ€based normative data tool for assessing cognitive performance in healthy older Australians. Medical Journal of Australia, 2011, 194, S12-4.	1.7	3
131	Comparing the Performance of the HADS and the GDS-15 in the AIBL Study. International Psychogeriatrics, 2015, 27, 1577-1578.	1.0	3
132	Aggregation of Abnormal Memory Scores and Risk of Incident Alzheimer's Disease Dementia: A Measure of Objective Memory Impairment in Amnestic Mild Cognitive Impairment. Journal of the International Neuropsychological Society, 2021, 27, 146-157.	1.8	3
133	The Support Person's Preferences and Perspectives of Physical Activity Programs for Older Adults With Cognitive Impairment. Frontiers in Public Health, 2021, 9, 704561.	2.7	3
134	A surface based approach for cortical thickness comparison between PiB+ and PiB- healthy control subjects. Proceedings of SPIE, 2012, , .	0.8	2
135	Lifestyle and late life cognitive health: sufficient evidence to act now?. International Psychogeriatrics, 2012, 24, 683-688.	1.0	2
136	Alcohol Use, Mental Health, and Functional Capacity as Predictors of Workplace Disability in a Cohort With Manifest Huntington's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2020, 32, 235-243.	1.8	2
137	IC-01-03: Larger temporal volume in asymptomatic elderly with high versus low beta-amyloid deposition., 2010, 6, S2-S3.		1
138	Depression and physical activity research in older age: An important gap to fill. Psychology of Sport and Exercise, 2019, 43, 1-3.	2.1	1
139	Effects of a physical activity intervention on brain atrophy in older adults at risk of dementia: a randomized controlled trial. Brain Imaging and Behavior, 2021, 15, 2833-2842.	2.1	1
140	Supervised method to build an atlas database for multi-atlas segmentation-propagation. Proceedings of SPIE, $2010, , .$	0.8	0
141	IC-03-01: Dynamic of beta-amyloid deposition in healthy elderly, mild cognitive impairment and alzheimer's disease: a PiB-PET longitudinal study. , 2011, 7, S6-S6.		0
142	O4-07-01: Biomarker-based prediction of cognitive decline in 270 nondemented older individuals: Three-year follow-up results from the Australian Imaging Biomarkers and Lifestyle study of Aging (AIBL)., 2013, 9, P695-P695.		0